<DOC>
	<DOCNO>NCT02687711</DOCNO>
	<brief_summary>Study first study commercialization brivaracetam . It design collect real world information effectiveness brivaracetam patient Partial Onset Seizure epislepsy treat standard clinical practice .</brief_summary>
	<brief_title>Study Look How Effective Briviact add-on Treatment Patients With Epilepsy With Partial Onset Seizures</brief_title>
	<detailed_description>EP0077 12 month , multicenter , noninterventional study ( NIS ) conduct specialized site approximately 10 European country . Patients treat accord usual medical diagnostic procedure therapy ; commercially available brivaracetam prescribe accord normal clinical practice current Summary Product Characteristics ( SmPC ) Europe brivaracetam ( BRV ) . The prescription BRV clearly separate decision include patient study . No additional diagnostic monitoring procedure apply patient . The primary objective study determine BRV retention 12 month period measure effectiveness real world setting . The secondary objective study assess seizure control BRV treatment .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Patient never treat brivaracetam ( BRV ) prior enrollment NonInterventional Study ( NIS ) The decision treat physician prescribe BRV make independently participation NIS Patient male female â‰¥16 year age Patient clinical diagnosis epilepsy POS without secondary generalization Patient use epilepsy/seizure diary . No specific exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Non-interventional ( NIS )</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Partial Onset Seizures ( POS )</keyword>
	<keyword>add-on therapy</keyword>
</DOC>